Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $108.3 million.

  • Myriad Genetics' Accumulated Expenses fell 260.79% to $108.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.3 million, marking a year-over-year decrease of 260.79%. This contributed to the annual value of $119.0 million for FY2024, which is 447.76% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Accumulated Expenses is $108.3 million, which was down 260.79% from $100.6 million recorded in Q2 2025.
  • Myriad Genetics' Accumulated Expenses' 5-year high stood at $164.3 million during Q2 2023, with a 5-year trough of $83.1 million in Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $108.3 million (2025), whereas its average is $113.9 million.
  • In the last 5 years, Myriad Genetics' Accumulated Expenses soared by 14954.13% in 2021 and then tumbled by 4773.28% in 2022.
  • Myriad Genetics' Accumulated Expenses (Quarter) stood at $161.7 million in 2021, then plummeted by 41.68% to $94.3 million in 2022, then rose by 20.78% to $113.9 million in 2023, then increased by 4.48% to $119.0 million in 2024, then dropped by 8.99% to $108.3 million in 2025.
  • Its Accumulated Expenses was $108.3 million in Q3 2025, compared to $100.6 million in Q2 2025 and $112.1 million in Q1 2025.